Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Diane Martel"'
Autor:
William G. Cioffi, Paul A. Akerman, Diane Martel, John Mark Barnett, Tom Miner, Melissa Remis, Dennis Cruff, T. Dipetrillo, David A. Iannitti, Christine Maia-Acuna, Howard Safran, Teresa Kennedy
Publikováno v:
American Journal of Clinical Oncology. 28:570-575
A phase I trial was conducted to determine the maximally tolerated dose of erlotinib with concurrent gemcitabine, paclitaxel, and radiation for patients with locally advanced pancreatic cancer and to gather preliminary data on maintenance erlotinib a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a115219b79e43237589bba816f6c4d41
https://doi.org/10.1097/01.coc.0000184682.51193.00
https://doi.org/10.1097/01.coc.0000184682.51193.00
Autor:
Kayla Rosati, David Berz, Kevin P. Charpentier, Kimberly Perez, Thomas Miner, Joel Victor, Santiago Aparo, Gregory Dubel, Denise Luppe, Diane Martel, Pamela Bakalarski, Yoko Eng, Katherine Faricy-Anderson, Howard Safran, Patti Wingate, Angela Plette, Kalyan Mantripragada, Andreas Kaubisch, Joseph Espat
Publikováno v:
American journal of clinical oncology. 38(1)
Purpose To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. Materials and methods Patients with advanced HCC who progressed on or were intolerant to sorafenib w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83e398be6d4340395e18651eb66499ad
https://pubmed.ncbi.nlm.nih.gov/23648434
https://pubmed.ncbi.nlm.nih.gov/23648434
Autor:
Kalyan Mantripragada, Kenneth D. Bishop, Kayla Rosati, Lynn Shaw, Trevor Clark Austin, Kristen Mitchell, Kimberly Perez, Lindsay Houlihan, Alise Lombardo, Howard Safran, Kevin P. Charpentier, Diane Martel
Publikováno v:
Journal of Clinical Oncology. 32:4123-4123
4123 Background: The contribution of irinotecan to the efficacy of FOLFIRINOX in pancreatic cancer is uncertain. The addition of irinotecan to gemcitabine was not superior to gemcitabine alone in p...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90ab31f098486e8422448a3f7cae0f34
https://doi.org/10.1200/jco.2014.32.15_suppl.4123
https://doi.org/10.1200/jco.2014.32.15_suppl.4123
Autor:
Kayla Rosati, Kevin P. Charpentier, Denise Luppe, Jack R. Wands, Debora Isdale, Kalyan Mantripragada, Howard Safran, Joel Victor, Angela Marie Taber, Kimberly Perez, Andreas Kaubisch, Yoko Eng, Patti Wingate, Joseph Espat, Gregory J. Dubel, Diane Martel, David Berz, Thomas J. Miner, Katherine E. Faricy-Anderson, Pamela Bakalarski
Publikováno v:
Journal of Clinical Oncology. 30:4098-4098
4098 Background: Lenalidomide inhibits fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and multiple tumor growth pathways. There is no standard of care for patients who progress after sorafenib. Therefore, we performed a pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e8857a73b855597b91a9eea737a96bf
https://doi.org/10.1200/jco.2012.30.15_suppl.4098
https://doi.org/10.1200/jco.2012.30.15_suppl.4098
Autor:
N. Saba, C. Maia, Paul A. Akerman, David P. Harrington, Thomas J. Miner, Thomas Ng, Diane Martel, Devon Evans, D. Benton, Howard Safran
Publikováno v:
Journal of Clinical Oncology. 24:14046-14046
14046 Background: The Brown University Oncology Group has attempted to modify the regimen of docetaxel, cisplatin and fluorouracil (DCF) to reduce toxicity, simplify administration and maintain efficacy. We have a completed a phase I/II study of week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::589c390ee3c0b7d0816fb143a6e84856
https://doi.org/10.1200/jco.2006.24.18_suppl.14046
https://doi.org/10.1200/jco.2006.24.18_suppl.14046